Drugs / KN3601
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07423572 | Feb 2026 → Feb 2028 expected | idiopathic membranous glomerulonephritis | The First Affiliated Hospital of Zhejiang Chinese Medical University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07246096 | Feb 2026 → Jul 2027 expected | Sjogren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, rheumatoid arthritis, systemic lupus erythematosus +1 | Changhai Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT07241468 | Nov 2025 → Dec 2026 expected | kidney disorder | Changhai Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07558850 | May 2026 → Jan 2028 expected | dermatomyositis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN3601 | “A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cell injection (KN3601) in patients with...” NCT07241468 ↗3“Single dose of CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (KN3601) will infused using dose-escalation strategy.” NCT07423572 ↗ “Dose escalation will be performed for the single dose injection of anti-CD19/BCMA CAR T cells (KN3601)” NCT07246096 ↗ “Single dose of anti-CD19/BCMA CAR T cells (KN3601) will infused using dose-escalation strategy.” NCT07558850 ↗ |
| Modality | Cell therapy | “anti-CD19/BCMA U CAR T cell injection (KN3601)” NCT07241468 ↗ |
| Route | Other | “anti-CD19/BCMA U CAR T cells infusion” NCT07241468 ↗ |
| Target | CD19 | “CD19/BCMA-Targeted” NCT07423572 ↗ |